Gastrointestinal and Hepatobiliary · Hepatocellular carcinoma · 2026 update
BCLC Staging for Hepatocellular Carcinoma: 2026 Update
The Barcelona Clinic Liver Cancer staging system integrates HCC burden, liver function and cancer-related performance status to estimate prognosis and guide treatment strategy.
Purpose
To stage hepatocellular carcinoma by integrating tumour burden, liver function and cancer-related Eastern Cooperative Oncology Group performance status, while linking each stage to an evidence-based treatment strategy.
| Stage | Tumour burden | Liver function and ECOG PS | Treatment direction |
|---|---|---|---|
| 0 — Very early | Single HCC ≤2 cm; no vascular invasion or extrahepatic spread | Preserved liver function; ECOG PS 0 | Curative-intent local treatment: ablation or resection; selected patients may undergo transplantation, TARE or external-beam radiotherapy |
| A — Early | Single HCC >2 cm irrespective of maximum size, or 2–3 nodules all ≤3 cm; no vascular invasion or extrahepatic spread | Preserved liver function; ECOG PS 0 | Curative-intent treatment with resection, transplantation or ablation; selected patients may receive TARE or external-beam radiotherapy |
| B — Intermediate | Multifocal HCC beyond stage A: >3 nodules, or 2–3 nodules with at least one >3 cm; no vascular invasion or extrahepatic spread | Preserved liver function; ECOG PS 0 | Assess transplantation eligibility; TACE for suitable well-defined arterialised tumours, or systemic therapy when disease is diffuse, infiltrative or unsuitable for selective treatment |
| C — Advanced | Portal invasion and/or extrahepatic spread, or cancer-related ECOG PS 1–2 | Liver function adequate for active treatment | Systemic therapy; individualised locoregional treatment may be considered only in selected multidisciplinary settings |
| D — Terminal | Any tumour burden | Cancer-related ECOG PS 3–4 and/or end-stage liver function without a feasible transplantation option | Symptom-directed and palliative care; assess transplantation when severe liver dysfunction is the determining factor and transplantation remains feasible |
How to use it
- The 2026 update retains the five BCLC stages used in 2022 and explicitly defines stage B multifocal disease as more than three nodules, or two to three nodules with at least one larger than 3 cm.
- Stage assignment integrates tumour burden, hepatic functional reserve and cancer-related performance status; performance limitation from an unrelated comorbidity should not automatically upstage the HCC.
- Stage B is heterogeneous: transplantation criteria, tumour distribution, portal venous flow and the feasibility of selective arterial catheterisation determine whether transplantation, TACE or systemic therapy is appropriate.
- The treatment linked to a stage is a starting strategy rather than an inflexible rule; treatment-stage migration and the 2026 CUSE framework support individualised multidisciplinary decisions.
Common mistake
Do not classify a large solitary HCC as BCLC-B solely because of its size. With preserved liver function, ECOG PS 0 and no vascular invasion or extrahepatic spread, a solitary tumour larger than 2 cm remains BCLC-A.
Exam pearl
Remember 0–A–B–C–D as ≤2 cm solitary, early curative burden, multifocal beyond A, vascular or extrahepatic spread or cancer-related PS 1–2, and terminal liver function or cancer-related PS 3–4.
Viva questions
- What is the BCLC staging system?
- The Barcelona Clinic Liver Cancer system stages hepatocellular carcinoma by integrating tumour burden, liver function and cancer-related ECOG performance status, and links each stage to a treatment strategy.
- Enumerate the five BCLC stages.
- Stage 0 is very early, A is early, B is intermediate, C is advanced and D is terminal stage.
- What defines BCLC stage 0?
- A single HCC measuring 2 cm or less, with preserved liver function, ECOG performance status 0 and no vascular invasion or extrahepatic spread.
- What defines BCLC stage A?
- A solitary HCC larger than 2 cm irrespective of size, or two to three nodules each measuring 3 cm or less, with preserved liver function and ECOG performance status 0.
- How does the 2026 BCLC update define multifocal stage B disease?
- Stage B includes more than three nodules, or two to three nodules with at least one larger than 3 cm, provided there is no vascular invasion or extrahepatic spread and liver function and performance status are preserved.
- Which BCLC stage is conventionally associated with TACE?
- BCLC-B. TACE is most appropriate for well-defined arterialised tumours when portal flow is preserved and selective catheterisation is feasible; not every stage B patient is a TACE candidate.
- What defines BCLC stage C?
- Portal invasion, extrahepatic spread or cancer-related ECOG performance status 1–2 in a patient whose liver function permits active treatment. Systemic therapy is the usual treatment direction.
- What is the common staging error with a large solitary HCC?
- A large solitary HCC should not automatically be called BCLC-B. If liver function is preserved, performance status is 0 and there is no vascular invasion or extrahepatic spread, it remains BCLC-A.